HBL - Hadasit Bio-Holdings Ltd

OTCPK:HSIT.F Stock Report

Market Cap: US$1.6m

HBL - Hadasit Bio-Holdings Past Earnings Performance

Past criteria checks 0/6

HBL - Hadasit Bio-Holdings's earnings have been declining at an average annual rate of -32.1%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 106.9% per year.

Key information

-32.1%

Earnings growth rate

-32.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-106.9%
Return on equity-491.6%
Net Marginn/a
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown
Beta

How HBL - Hadasit Bio-Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:HSIT.F Revenue, expenses and earnings (ILS Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-2920
30 Sep 230-2920
30 Jun 230-2920
31 Mar 230-3030
31 Dec 220-3130
30 Sep 220-2730
30 Jun 220-2220
31 Mar 220320
31 Dec 2102820
30 Sep 2103120
30 Jun 2103320
31 Mar 2103220
31 Dec 2003120
30 Sep 2002130
30 Jun 2001130
31 Mar 200-630
31 Dec 190-2230
30 Jun 190-1430
31 Mar 190-330
31 Dec 180730
30 Jun 180324-7
31 Mar 180334-4
31 Dec 1703440
30 Sep 17013616
30 Jun 17013415
31 Mar 1706513
31 Dec 1601130
30 Sep 160-668
30 Jun 160-966
31 Mar 160-1066
31 Dec 150-1768
30 Sep 150-18710
30 Jun 150-16611
31 Mar 150-12610
31 Dec 140-657
30 Sep 140-857
30 Jun 140-1156
31 Mar 140-1757
31 Dec 130-1558
30 Sep 130-1358

Quality Earnings: HSIT.F is currently unprofitable.

Growing Profit Margin: HSIT.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HSIT.F is unprofitable, and losses have increased over the past 5 years at a rate of 32.1% per year.

Accelerating Growth: Unable to compare HSIT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HSIT.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: HSIT.F has a negative Return on Equity (-491.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.